273722-75-1

Usage

Uses

Used in Fragrance and Flavoring Industry:
3-(Cyclopentyloxy)benzaldehyde is used as a key ingredient in the creation of fragrances and flavorings for its distinctive floral and woody scent, enhancing the sensory experience of various consumer products.
Used in Organic Synthesis:
3-(Cyclopentyloxy)benzaldehyde is utilized as a building block in the synthesis of a variety of organic compounds, such as dyes, pharmaceuticals, and agrochemicals, due to its reactivity with other chemicals to form new compounds.
Used in Research and Development:
As a reagent in organic synthesis, 3-(Cyclopentyloxy)benzaldehyde is employed in research and development for the creation of novel compounds and materials, contributing to advancements in various scientific fields.

InChI:InChI=1/C12H14O2/c13-9-10-4-3-7-12(8-10)14-11-5-1-2-6-11/h3-4,7-9,11H,1-2,5-6H2

Upstream product

• 137-43-9 Cyclopentyl bromide 
• 100-83-4 meta-hydroxybenzaldehyde 
• 96-41-3 Cyclopentanol 

Downstream Products

• 158860-99-2 3-(cyclopentyloxy)benzoic acid 
• 1217315-35-9 C₂₄H₃₆N₂O₃ 
• 1309653-52-8 C₁₆H₂₃NO₂S 
• 1198223-03-8 (R)-1-(3-(cyclopentyloxy)phenyl)ethan-1-amine hydrochloride 
• 1309653-53-9 (S)-N-((R)-1-(3-(cyclopentyloxy)phenyl)ethyl)-2-methylpropane-2-sulfinamide 
• 1262151-06-3 6-amino-5-{[(3-cyclopentyloxy)benzylidene]amino}-1,3-dimethyluracil 
• 1228384-83-5 8-[3-(cyclopentyloxy)phenyl]-1,3-dimethylxanthine 
• 1193782-49-8 (5R,7S)-8-[3-(cyclopentyloxy)benzyl]-1-(3-fluorophenyl)-7-methyl-2-thia-1,3,8-triazaspiro[4.5]decane 2,2-dioxide 
• 1447824-50-1 1-(azido(tert-butylperoxy)methyl)-3-(cyclopentyloxy)benzene 
• 1198223-04-9 (S,E)-N-(3-(cyclopentyloxy)benzylidene)-2-methylpropane-2-sulfinamide 
• 1309653-68-6 (R)-4-(bromomethyl)-N-(1-(3-(cyclopentyloxy)phenyl)ethyl)-benzenesulfonamide 
• 1380335-99-8 (R,E)-ethyl 5-(N-(1-(3-(cyclopentyloxy)phenyl)ethyl)-N-(methoxymethyl)sulfamoyl)pent-2-enoate 
• 1198225-16-9 (R)-N-(1-(3-(cyclopentyloxy)phenyl)ethyl)-3-hydroxy-N-(methoxymethyl)propane-1-sulfonamide 

Relevant academic research and scientific papers

Structure-aided optimization of non-nucleoside M. tuberculosis thymidylate kinase inhibitors

Mycobacterium tuberculosis thymidylate kinase (MtTMPK) has emerged as an attractive target for rational drug design. We recently investigated new families of non-nucleoside MtTMPK inhibitors in an effort to diversify MtTMPK inhibitor chemical space. We here report a new series of MtTMPK inhibitors by combining the Topliss scheme with rational drug design approaches, fueled by two co-crystal structures of MtTMPK in complex with developed inhibitors. These efforts furnished the most potent MtTMPK inhibitors in our assay, with two analogues displaying low micromolar MIC values against H37Rv Mtb. Prepared inhibitors address new sub-sites in the MtTMPK nucleotide binding pocket, thereby offering new insights into its druggability. We studied the role of efflux pumps as well as the impact of cell wall permeabilizers for selected compounds to potentially provide an explanation for the lack of correlation between potent enzyme inhibition and whole-cell activity.

ANTI-TUMOR EFFECT POTENTIATOR

There is provided an agent for potentiating the effects of an anti-tumor agent. An anti-tumor effect potentiator containing, as an active ingredient, a uracil compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: wherein X represents a C1-5 alkylene group and one of methylene groups constituting the alkylene group is optionally substituted with an oxygen atom; R1 represents a hydrogen atom or a C1-6 alkyl group; R2 represents a hydrogen atom or a halogen atom; and R3 represents a C1-6 alkyl group, a C2-6 alkenyl group, a C3-6 cycloalkyl group, a (C3-6 cycloalkyl) C1-6 alkyl group, a halogeno-C1-6 alkyl group or a saturated heterocyclic group.

NOVEL URACIL COMPOUND HAVING INHIBITORY ACTIVITY ON HUMAN DEOXYURIDINE TRIPHOSPHATASE OR SALT THEREOF

Provided is a uracil compound or a salt thereof, which has potent human dUTPase inhibitory activity and is useful as, for example, an antitumor drug. A uracil compound represented by the general formula (I) or a salt thereof: wherein n represents an integer of 1 to 3; X represents a bond, an oxygen atom, a sulfur atom, or the like; Y represents a linear or branched alkylene group having 1 to 8 carbon atoms, or the like; and Z represents -SO2NR1R2 or -NR3SO2-R4, wherein R1 and R2 each represent an alkyl group having 1 to 6 carbon atoms, an aralkyl group which is optionally substituted, or the like; R3 represents an alkyl group having 1 to 6 carbon atoms, or the like; and R4 represents an aromatic hydrocarbon group, an unsaturated heterocyclic group, or the like.

Synthesis of 8-(cyclopentyloxy)phenyl substituted xanthine derivatives as adenosine A2A ligands

The present paper describes the synthesis of a series of 8-(cyclopentyloxy)phenyl-xanthines and their evaluation for affinity for A 1 and A2 adenosine receptors using radioligand binding assays. The effects of moving the cyclopentyloxy substituent with or without an ortho methoxy group on the various positions of the 8-phenyl ring have been studied. The vanilloid based xanthines 8-[4-(cyclopentyloxy)-3-methoxyphenyl]-1, 3-dimethylxanthine (6a) (Ki = 100 nM) and 8-[(4-cyclopentyloxy)-3- methoxyphenyl]-3-methyl-1-propylxanthine (12) (Ki = 150 nM) displayed the highest affinity at A2A receptors as well as over 1000 fold selectivity over the A1 adenosine receptor subtype. ECV · Editio Cantor Verlag, Aulendorf (Germany).

Selective Type IV Phosphodiesterase Inhibitors as Antiasthmatic Agents. The Syntheses and Biological Activities of 3-(Cyclopentyloxy)-4-methoxybenzamides and Analogues

The syntheses and biological activities of a number of benzamide derivatives, designed from rolipram, which are selective inhibitors of cyclic AMP-specific phosphodiesterase (PDE IV), are described.The effects of changes to the alkoxy groups, amide linkag